Elevated D-dimer is independently associated with endothelial dysfunction: a cross-sectional study in HIV-infected adults on antiretroviral therapy

Antivir Ther. 2012;17(7):1345-9. doi: 10.3851/IMP2297. Epub 2012 Aug 9.

Abstract

Background: D-Dimer elevations have been associated with a striking increase in mortality in HIV-infected patients. However, D-Dimer has not been directly linked to endothelial dysfunction in HIV.

Methods: In this cross-sectional study, we used flow-mediated dilation (FMD) of the brachial artery to measure endothelial function and several biomarkers to measure systemic inflammation and coagulation activation in HIV-infected adults on stable antiretroviral therapy with HIV-1 RNA levels <400 copies/ml. Multivariable linear regression was used to model FMD by these markers, traditional cardiovascular risk factors and HIV-related characteristics.

Results: Analysis included 98 subjects (88% male, median age 47.5 years, CD4(+) T-cells 578.5 cells/mm(3)); all on ART (52% on protease inhibitors). The only factors independently associated with FMD were D-Dimer and body mass index.

Conclusions: We show for the first time an independent association between D-Dimer and endothelial dysfunction in virologically suppressed, HIV-infected adults on stable antiretroviral therapy, potentially explaining the link between D-Dimer and mortality in HIV.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biomarkers / metabolism
  • Body Mass Index
  • Brachial Artery / diagnostic imaging
  • Brachial Artery / drug effects
  • Brachial Artery / pathology
  • CD4 Lymphocyte Count
  • Cardiovascular Diseases / chemically induced
  • Cardiovascular Diseases / metabolism
  • Cardiovascular Diseases / pathology
  • Cross-Sectional Studies
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / metabolism
  • Endothelium, Vascular / physiopathology*
  • Female
  • Fibrin Fibrinogen Degradation Products / metabolism*
  • HIV Infections / drug therapy*
  • HIV Infections / metabolism
  • HIV Infections / pathology
  • HIV Protease Inhibitors / adverse effects
  • HIV Protease Inhibitors / therapeutic use*
  • HIV-1 / pathogenicity
  • Humans
  • Inflammation / pathology
  • Interleukin-6 / blood
  • Linear Models
  • Male
  • Middle Aged
  • Models, Cardiovascular
  • RNA, Viral / blood
  • Risk Factors
  • Ultrasonography
  • Vasodilation

Substances

  • Biomarkers
  • Fibrin Fibrinogen Degradation Products
  • HIV Protease Inhibitors
  • IL6 protein, human
  • Interleukin-6
  • RNA, Viral
  • fibrin fragment D